Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer
Status:
Completed
Trial end date:
2012-10-04
Target enrollment:
Participant gender:
Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such
as bicalutamide, may lessen the amount of androgens made by the body. Selective estrogen
receptor modulators, such as raloxifene, may work together with bicalutamide to stop the
growth of prostate cancer.
PURPOSE: This clinical trial studies giving bicalutamide and raloxifene together in treating
patients with metastatic or hormone-refractory prostate cancer.